“It’s extremely expensive to translate a patent into bedside medical tools,” Myriad Genetics president Mark C. Capone said in a telephone interview.
“It’s extremely expensive to translate a patent into bedside medical tools,” Myriad Genetics president Mark C. Capone said in a telephone interview.
“It’s extremely expensive to translate a patent into bedside medical tools,” Myriad Genetics president Mark C. Capone said in a telephone interview.

National

Supreme Court to consider whether firms can patent genes, the essence of life

April 12, 2013 5:22 PM

  Comments  

Videos